37 results on '"Hakariya T"'
Search Results
2. Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods
- Author
-
Miyata, Y., primary, Mochizuki, Y., additional, Shida, Y., additional, Matsuo, T., additional, Hakariya, T., additional, Ohba, K., additional, Furusato, B., additional, Fukuoka, J., additional, and Sakai, H., additional
- Published
- 2017
- Full Text
- View/download PDF
3. 175 Does neoadjuvant hormonal therapy stimulate cancer cell dissemination via increasing of lymph vessel size in prostate cancer patients?
- Author
-
Miyata, Y., primary, Hakariya, T., additional, Shida, Y., additional, Asai, A., additional, Yasuda, T., additional, Matsuo, T., additional, Ohba, K., additional, and Sakai, H., additional
- Published
- 2016
- Full Text
- View/download PDF
4. 766 - Neoadjuvant hormonal therapy for patients with low risk prostate cancer stimulates lymphvessel invasion and shorten biochemical recurrence-free survival periods
- Author
-
Miyata, Y., Mochizuki, Y., Shida, Y., Matsuo, T., Hakariya, T., Ohba, K., Furusato, B., Fukuoka, J., and Sakai, H.
- Published
- 2017
- Full Text
- View/download PDF
5. EP-1091 SIMULTANOUS INTEGRATED BOOST USING INTENSITY MODULATED RADIATION THERAPY FOR HORMONE RESISTANT PROSTATE CANCER
- Author
-
Obata, S., primary, Ohta, Y., additional, Kan, T., additional, Kanegae, S., additional, Inoue, Y., additional, Matsuo, M., additional, and Hakariya, T., additional
- Published
- 2012
- Full Text
- View/download PDF
6. Efficacy of periprostatic nerve blockade during ultrasound-guided transrectal 10-core biopsy of the prostate
- Author
-
Hakariya, T., Hatada, T., and Miyata, Y.
- Subjects
Prostate -- Biopsy ,Prostate -- Analysis ,Prostate -- Research ,Health - Published
- 2006
7. Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.
- Author
-
Nakanishi S, Fukushima Y, Inokuchi J, Hakariya T, Kakinoki H, Enokida H, Chikui K, Matsuoka H, Shin T, Mukai S, Kamba T, Eto M, Imamura R, Noguchi M, Igawa T, Haga N, Kamoto T, Fujimoto N, and Saito S
- Subjects
- Humans, Male, Female, Japan epidemiology, Middle Aged, Retrospective Studies, Aged, Adult, Prognosis, Survival Rate, Hydrocortisone blood, Neoplasm Staging, Young Adult, Testosterone blood, Dehydroepiandrosterone Sulfate blood, Aldosterone blood, Adolescent, Aged, 80 and over, Adrenocortical Carcinoma pathology, Adrenocortical Carcinoma mortality, Adrenocortical Carcinoma blood, Adrenal Cortex Neoplasms pathology, Adrenal Cortex Neoplasms mortality, Adrenal Cortex Neoplasms blood, Adrenal Cortex Neoplasms therapy
- Abstract
Objective: Adrenocortical carcinoma is a rare condition, with limited comprehensive reports from Japan. This study aimed to review Japan's data on adrenocortical carcinoma by assessing information from 46 patients-with adrenocortical carcinoma across 10 Japanese university hospitals., Methods: We conducted a retrospective multi-institutional analysis of the clinical characteristics of adrenocortical carcinoma in Japan. We evaluated data from 46 patients across 10 university hospitals over 10 years and analyzed the relationship between clinicopathological characteristics and overall survival., Results: Five- and 10-year overall survival rates were 59% and 53%, respectively. Overall survival was significantly different among the tumor-node-metastasis system for adrenocortical carcinoma of the American Joint Committee on Cancer/International Union Against Cancer, with the worst prognosis in stage IV (p = 0.0044). In our cohort, neither the Weiss score nor the Ki-67 proliferation index correlated with overall survival. Adjuvant treatment did not yield improved overall survival, whereas resection of the primary tumor in stage IV disease was significantly associated with improved overall survival (p = 0.0262). Out of the cases evaluated for plasma hormones, plasma cortisol, aldosterone, testosterone, and DHEA-S levels were measured at 23%, 42%, 29%, and 62%, respectively, demonstrating higher levels than the upper normal limits., Conclusion: Patients with stage IV adrenocortical carcinoma had a poor prognosis; however, resection of the primary tumor in stage IV disease was associated with prolonged survival. The results of this study are expected to contribute to future treatment of adrenocortical carcinoma in Japan., (© 2024 The Authors. International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
8. GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
- Author
-
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, and Naito S
- Subjects
- Male, Humans, Androgen Antagonists adverse effects, Antineoplastic Combined Chemotherapy Protocols, Anilides adverse effects, Nitriles adverse effects, Tosyl Compounds adverse effects, Gonadotropin-Releasing Hormone, Lipids therapeutic use, Prostate-Specific Antigen, Prostatic Neoplasms
- Abstract
Objectives: To compare the effectiveness and safety of gonadotropin-releasing hormone (GnRH) antagonist monotherapy to combined androgen blockade (CAB) with a GnRH agonist and bicalutamide in patients with advanced hormone-sensitive prostate cancer (HSPC)., Methods: The study was conducted as KYUCOG-1401 trial (UMIN000014243) and enrolled 200 patients who were randomly assigned to either group A (GnRH antagonist monotherapy followed by the addition of bicalutamide) or group B (CAB by a GnRH agonist and bicalutamide). The primary endpoint was PSA progression-free survival. The secondary endpoints were the time to CAB treatment failure, radiographic progression-free survival, overall survival, changes in serum parameters, including PSA, hormones, and bone and lipid metabolic markers, and adverse events., Results: PSA progression-free survival was significantly longer in group B (hazard ratio [HR], 95% confidence interval [CI]; 1.40, 1.01-1.95, p = 0.041). The time to CAB treatment failure was slightly longer in group A (HR, 95% CI; 0.80, 0.59-1.08, p = 0.146). No significant differences were observed in radiographic progression-free survival or overall survival. The percentage of patients with serum testosterone that did not reach the castration level was higher at 60 weeks (p = 0.046) in group A. No significant differences were noted in the serum levels of bone metabolic or lipid markers between the two groups. An injection site reaction was more frequent in group A., Conclusions: The present results support the potential of CAB using a GnRH agonist and bicalutamide as a more effective treatment for advanced HSPC than GnRH antagonist monotherapy., (© 2023 The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
9. [Renal Cell Carcinomas in Patients on Chronic Dialysis].
- Author
-
Matsuda T, Mochizuki Y, Mukae Y, Nakanishi H, Mitsunari K, Matsuo T, Hakariya T, Ohba K, Miyata Y, Nishino T, and Sakai H
- Subjects
- Male, Humans, Female, Middle Aged, Renal Dialysis adverse effects, Prognosis, Nephrectomy adverse effects, Retrospective Studies, Carcinoma, Renal Cell surgery, Carcinoma, Renal Cell pathology, Kidney Neoplasms surgery, Kidney Neoplasms pathology, Kidney Failure, Chronic complications, Kidney Failure, Chronic therapy
- Abstract
Patients on chronic dialysis for end-stage renal disease (ESRD) show an increased incidence of renal cell carcinoma (RCC). We investigated the clinicopathological characteristics and outcomes of 54 patients who underwent nephrectomy for RCC due to ESRD between 1992 and 2019. The patients consisted of 44 men and 10 women, with a median age of 62.9 years. The median duration of dialysis before surgery was 12.9 years. The clinical stage of the 54 RCCs was stage I in 44, stage II in 1, stage III in 1, and stage IV in 8. With a median follow-up of 5.1 years after surgery, the 5-year cancer-specific and overall survival rates were 84.3 and 61.8%, respectively. Patients with symptomatic RCC had a longer period of dialysis, presented with larger tumors of higher grade and stage, and had worse prognosis compared with those with incidentally discovered RCC. Cox proportional hazards analysis performed with clinicopathological features and symptomatic/incidental detection showed that older age and symptomatic RCC were independently associated with worse overall survival. Our data show that early detection is important for a good prognosis.
- Published
- 2022
- Full Text
- View/download PDF
10. Preoperative Predictors of Lymph Node Invasion and Biochemical Recurrence in High-risk Prostate Cancer.
- Author
-
Shida Y, Hakariya T, Mitsunari K, Matsuo T, Ohba K, Miyata Y, and Sakai H
- Abstract
Aim: To evaluate the preoperative predictors of pathological lymph node (LN) metastasis and prognostic factors for postoperative biochemical recurrence (BCR) in robot-assisted radical prostatectomy with extended pelvic LN dissection in patients with D'Amico high-risk prostate cancer (PCa)., Patients and Methods: Overall, 107 patients with D'Amico high-risk PCa underwent robot-assisted radical prostatectomy with extended pelvic LN dissection without neoadjuvant or adjuvant therapy. BCR was defined as a prostate-specific antigen (PSA) level ≥0.2 ng/ml. Moreover, BCR-free survival rates were determined using Kaplan-Meier analysis. Logistic regression analysis was used to evaluate preoperative predictors of pathological LN metastasis. Cox regression analysis was used to evaluate the effects of preoperative and pathologic variables on BCR., Results: The median follow-up was 21 months, and the 5-year BCR-free survival rate was 59.8%. The positive LN rate was 21.5%. In multivariate analysis, the percentage of positive cores was a significant preoperative predictor of positive LNs. Patients with >50% positive cores (p=0.004) and PSA density (PSAD) >0.5 ng/ml/cc (p=0.005) had a high risk of having ≥3 positive LNs. In multivariate analysis, PSAD >0.5% was a significant preoperative predictor of BCR. Among the postoperative predictors, the number of positive LNs was significantly associated with BCR. Patients with ≥3 positive LNs (n=7) had significantly lower BCR-free survival rates than patients with one or two positive LNs (n=16) (p<0.001). Patients with >50% positive cores and PSAD >0.5 ng/ml/cc had a risk for a high number of positive LNs (≥3) that was strongly associated with shorter BCR-free survival (p<0.001)., Conclusion: The percentage of positive cores may be useful as a preoperative predictor of pathological LN metastasis in patients with high-risk PCa. Patients with >50% positive cores and PSAD >0.5 ng/ml/cc were found to have a high risk for ≥3 positive LNs and shorter BCR-free survival., Competing Interests: None., (Copyright 2022, International Institute of Anticancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
11. Surveillance of urachal abscess in the Kyushu-Okinawa area of Japan.
- Author
-
Tobu S, Udo K, Nishihara K, Miyajima S, Ando T, Onizuka C, Itesako T, Ashikari A, Hakariya T, Igawa T, Tanaka M, Shin T, Kamoto T, Nakagawa M, Saito S, Sakai H, Eto M, Kamba T, Fujimoto N, and Noguchi M
- Subjects
- Adolescent, Adult, Child, Humans, Japan epidemiology, Male, Middle Aged, Retrospective Studies, Umbilicus, Young Adult, Abscess diagnosis, Abscess epidemiology, Abscess therapy, Urachus diagnostic imaging, Urachus surgery
- Abstract
Objective: To report a multicenter experience with the management of urachal abscess treatment in Japan., Methods: This was a retrospective study of 263 cases of urachal abscess managed at 12 university hospitals in the Kyushu-Okinawa region over a 10-year period. Age, sex, abscess size, clinical symptoms, type of urachal remnants, and treatment were collected and analyzed., Results: The average age was 29.8 ± 18.1 years, with males accounting for approximately two-thirds of the study population. The average abscess size was 1.7 cm (range 0-11 cm). The most common presenting symptom was umbilical secretion (66%), followed by abdominal pain (46%). A total of 127 patients (48.3%) were treated with antibiotics alone, whereas 136 patients (51.7%) received surgical treatment. The surgical approach was laparotomy in 75 patients (61.0%) and laparoscopic surgery in 48 patients (39.0%). Regarding the type of urachal remnant, the urachus sinus (180 patients) accounted for 68.4% of the total., Conclusions: To our knowledge, this study represents the first report on urachal abscess treatment in Japan. Our data show that the clinical symptoms might vary depending on the type of urachus remnant. It should be noted that gross hematuria, a characteristic symptom of urachal cancer, is rare in patients with urachal abscess., (© 2021 The Japanese Urological Association.)
- Published
- 2021
- Full Text
- View/download PDF
12. [A CASE OF CONGENITAL UNILATERAL ABSENCE OF THE VAS DEFERENS WITH SUSPECTED IPSILATERAL RENAL AGENESIS].
- Author
-
Harada J, Kihara T, Kawada K, Gono S, Sagawa R, Kondo T, Yuno T, Shida Y, Hakariya T, Kosaka T, Dateki S, Miyata Y, and Sakai H
- Abstract
A 5-month-old boy was referred to our department to examine poor development of external genitalia. The patient was diagnosed with micropenis and bilateral impalpable testes, and testosterone replacement therapy was recommended. The testes remained impalpable at 14 months of age; therefore, laparoscopy was performed to explore intra-abdominal testes. The patient was incidentally diagnosed with congenital unilateral absence of the right vas deferens. A renal sonography performed after the operation revealed a high possibility of right renal agenesis. Congenital absence of the vas deferens is associated with a high probability of renal anomalies. It is, therefore, essential to pay careful attention to renal dysfunction.
- Published
- 2021
- Full Text
- View/download PDF
13. Rare case of penile fracture caused by an injury to the crus penis: Delayed repair using the transperineal approach.
- Author
-
Harada J, Shida Y, Gono S, Masato M, Yuno T, Hakariya T, Kihara T, Maeda K, Miyata Y, and Sakai H
- Abstract
Introduction: Penile fracture is a rare urologic emergency, and its surgical treatment is selected based on the damaged site of the penile corpus cavernosum. Penile fractures at the site of the crus penis are quite rare, and there is controversy regarding the preferred method of surgical repair., Case Presentation: A 25-year-old Asian man was injured when rolling over in bed. Magnetic resonance imaging showed a tear in the left crus of the penis with a hematoma. Delayed surgery was successfully performed using the transperineal approach. He did not experience pain, dysuria, or erectile dysfunction postoperatively., Conclusion: Delayed surgical repair using transperineal approach may be useful for penile fractures associated with penile crus injuries., Competing Interests: The authors declare no conflict of interest., (© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.)
- Published
- 2020
- Full Text
- View/download PDF
14. Diagnostic Impacts of Clinical Laboratory Based p2PSA Indexes on any Grade, Gleason Grade Group 2 or Greater, or 3 or Greater Prostate Cancer and Prostate Specific Antigen below 10 ng/ml.
- Author
-
Ito K, Yokomizo A, Tokunaga S, Arai G, Sugimoto M, Akakura K, Hasumi H, Sakai H, Ouraji A, Oki R, Kashiwagi E, Kobori Y, Hirama H, Kitoh H, Uemura H, Hakariya T, and Suzuki K
- Subjects
- Aged, Biopsy, Diagnosis, Differential, Humans, Male, Middle Aged, Neoplasm Grading, Prospective Studies, Prostatic Neoplasms blood, Prostatic Neoplasms pathology, Protein Precursors, Biomarkers, Tumor blood, Prostate-Specific Antigen blood, Prostatic Neoplasms diagnosis
- Abstract
Purpose: The PROPHET (Prostate Cancer: Prostate Health Index Trial) is a prospective study to clarify the diagnostic impact of laboratory based and prostate volume adjusted p2PSA ([-2] proenzyme prostate specific antigen) related indexes on prostate cancer and clinically significant prostate cancer with prostate specific antigen less than 10 ng/ml., Materials and Methods: Between April 2015 and March 2017, 421 men 50 to 79 years old in the prostate specific antigen range above age specific cutoffs and below 10 ng/ml were registered in the PROPHET. We investigated the diagnostic impacts of various clinical laboratory based free prostate specific antigen related and p2PSA related indexes on any grade and high Gleason grade group prostate cancer., Results: Of the 363 eligible participants 179, 141 and 80 were diagnosed with any grade, and Gleason Grade Group 2-5 and 3-5 prostate cancer, respectively. The AUC-ROCs distinguishing nonprostate cancer vs prostate cancer, nonprostate cancer plus low Gleason Grade Group and low volume vs remaining prostate cancer with a higher Gleason Grade group or a higher volume on the PHI (Prostate Health Index) were significantly superior to the AUC-ROCs of prostate specific antigen and free-to-total prostate specific antigen. At 90% sensitivity in all investigated p2PSA related indexes the false-positive rate was superior to that of prostate specific antigen and free-to-total prostate specific antigen in any group comparison in terms of the Gleason Grade Group and positive biopsy cores. In 35% to 42% of men without prostate cancer and/or those with less aggressive prostate cancer the PHI would avoid unnecessary biopsy., Conclusions: Laboratory based p2PSA related indexes were significantly superior for detecting clinically significant prostate cancer compared to free-to-total prostate specific antigen. The indexes those would avoid up to 42% of prostate biopsies in men without aggressive cancer while maintaining 90% sensitivity.
- Published
- 2020
- Full Text
- View/download PDF
15. Three cases of brain metastasis from castration-resistant prostate cancer.
- Author
-
Shida Y, Hakariya T, Miyata Y, and Sakai H
- Abstract
Brain metastasis from prostate cancer may be becoming more common and may be associated with occurrence of diffuse systemic metastases., Competing Interests: The authors declare that they have no competing interests., (© 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
16. Stage-specific embryonic antigen-4 is a histological marker reflecting the malignant behavior of prostate cancer.
- Author
-
Nakamura Y, Miyata Y, Matsuo T, Shida Y, Hakariya T, Ohba K, Taima T, Ito A, Suda T, Hakomori SI, Saito S, and Sakai H
- Subjects
- Aged, Apoptosis, Biopsy, Humans, Lymph Nodes metabolism, Lymph Nodes pathology, Lymphatic Metastasis, Lymphocytes, Tumor-Infiltrating pathology, Male, Middle Aged, Multivariate Analysis, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Prostatectomy, Prostatic Neoplasms metabolism, Prostatic Neoplasms mortality, Prostatic Neoplasms surgery, Survival Analysis, Biomarkers, Tumor metabolism, Glycosphingolipids metabolism, Lymphocytes, Tumor-Infiltrating metabolism, Prostatic Neoplasms diagnosis, Stage-Specific Embryonic Antigens metabolism
- Abstract
Stage-specific embryonic antigen-4 (SSEA-4), a specific marker for pluripotent stem cells, plays an important role in the malignant behavior of several cancers. Here, SSEA-4 expression was evaluated by immunohistochemistry using monoclonal antibody RM1 specific to SSEA-4 in 181 and 117 prostate cancer (PC) specimens obtained by biopsy and radical prostatectomy (RP), respectively. The relationships between SSEA-4 expression in cancer cells or the presence of SSEA-4-positive tumor-infiltrating immune cells (TICs) and clinicopathological parameters were analyzed. SSEA-4 expression in cancer cells was significantly associated with Gleason score, local progression, and lymph node and distant metastasis. In RP specimens, high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs were significant predictors of pT3, i.e., invasion and worse biochemical recurrence (BCR) after RP, respectively, in univariate analysis. In contrast, combination of high SSEA-4 expression in cancer cells and the presence of SSEA-4-positive TICs was an independent predictor for pT3 and BCR in multivariate analysis. Biologically this combination was also independently associated with suppression of apoptosis. Thus, the co-expression of SSEA-4 in cancer cells and TICs may have crucial roles in the malignant aggressiveness and prognosis of PC. Invasive potential and suppression of apoptosis may be linked to SSEA-4 expression.
- Published
- 2019
- Full Text
- View/download PDF
17. Successful laparoscopic resection of a paraganglioma immediately behind the inferior vena cava and bilateral renal veins.
- Author
-
Hakariya T, Shida Y, Ito H, Ueda Y, Kurata H, Ohtsubo A, Miyata Y, Sakai H, and Furusato B
- Abstract
Introduction: Paragangliomas have a rich blood flow and are located around large vessels; thus, resection is often difficult. We herein report a case of a paraganglioma that was located immediately behind the inferior vena cava and bilateral renal veins and successfully resected by laparoscopic surgery., Case Presentation: A 72-year-old man was incidentally diagnosed with a 7-cm retroperitoneal mass immediately behind the inferior vena cava and bilateral renal veins by computed tomography. The mass was diagnosed as a retroperitoneal paraganglioma. The patient underwent laparoscopic surgery in the left lateral decubitus position. The tumor was dissected completely with no complications., Conclusion: Resection of retroperitoneal paragangliomas is often a surgical challenge. The feasibility of the laparoscopic approach to such paragangliomas was demonstrated in the present case., Competing Interests: The authors declare no conflict of interest., (© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.)
- Published
- 2019
- Full Text
- View/download PDF
18. Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer.
- Author
-
Miyata Y, Shida Y, Hakariya T, and Sakai H
- Subjects
- Anticarcinogenic Agents chemistry, Anticarcinogenic Agents therapeutic use, Antioxidants chemistry, Apoptosis drug effects, Cell Proliferation drug effects, Humans, Male, Polyphenols chemistry, Prostatic Neoplasms pathology, Antioxidants therapeutic use, Polyphenols therapeutic use, Prostatic Neoplasms drug therapy, Tea chemistry
- Abstract
Prostate cancer is the most common cancer among men. Green tea consumption is reported to play an important role in the prevention of carcinogenesis in many types of malignancies, including prostate cancer; however, epidemiological studies show conflicting results regarding these anti-cancer effects. In recent years, in addition to prevention, many investigators have shown the efficacy and safety of green tea polyphenols and combination therapies with green tea extracts and anti-cancer agents in in vivo and in vitro studies. Furthermore, numerous studies have revealed the molecular mechanisms of the anti-cancer effects of green tea extracts. We believe that improved understanding of the detailed pathological roles at the molecular level is important to evaluate the prevention and treatment of prostate cancer. Therefore, in this review, we present current knowledge regarding the anti-cancer effects of green tea extracts in the prevention and treatment of prostate cancer, with a particular focus on the molecular mechanisms of action, such as influencing tumor growth, apoptosis, androgen receptor signaling, cell cycle, and various malignant behaviors. Finally, the future direction for the use of green tea extracts as treatment strategies in patients with prostate cancer is introduced.
- Published
- 2019
- Full Text
- View/download PDF
19. [A Case of Giant Adrenal Endothelial Cyst that was Discovered in Pregnancy and Caused Bleeding Three Years Later].
- Author
-
Araki K, Hakariya T, Shida Y, Miyata Y, Tabata K, Abe K, Fukuoka J, and Sakai H
- Subjects
- Adrenalectomy, Adult, Female, Humans, Pregnancy, Tomography, X-Ray Computed, Adrenal Gland Diseases, Adrenal Gland Neoplasms, Cysts etiology, Hemorrhage complications, Pregnancy Complications diagnosis
- Abstract
A 39-year-old woman was referred to our hospital after incidental detection of a hypoechoic abdominal mass on ultrasonography at the 11th week of gestation. Magnetic resonance imaging confirmed a 20 cm cystic lesion just cephalad to the left kidney. The patient delivered in the 40th week of gestation without complications. After 3 years of follow-up, she presented with acute left flank pain. Physical examination revealed pale palpebral conjunctiva and abdominal fullness. Contrast-enhanced computed tomography confirmed a 21 × 17 × 15 cm hemorrhagic cyst arising from the left adrenal gland. Laparoscopic left adrenalectomy was performed. Pathological examination revealed a vascular cyst (endothelial cyst) of the adrenal gland. Surgical intervention is indicated for large adrenal cysts which may cause bleeding into the cavity.
- Published
- 2019
- Full Text
- View/download PDF
20. Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men.
- Author
-
Hakariya T, Shida Y, Tsurusaki T, Watanabe J, Furukawa M, Matsuya F, Miyata Y, and Sakai H
- Subjects
- Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Benzamides, Estrogens therapeutic use, Humans, Japan epidemiology, Male, Middle Aged, Multivariate Analysis, Neoplasm Staging, Nitriles, Phenylthiohydantoin therapeutic use, Prostatic Neoplasms, Castration-Resistant mortality, Retrospective Studies, Survival Analysis, Treatment Outcome, Drug Resistance, Neoplasm, Ethinyl Estradiol therapeutic use, Phenylthiohydantoin analogs & derivatives, Prostate-Specific Antigen blood, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Objective: To elucidate the effect of prior use of ethinylestradiol on enzalutamide treatment for men with castration-resistant prostate cancer., Methods: We retrospectively analyzed data from 99 consecutive patients (median age 72 years, range 50-88 years) treated with enzalutamide for castration-resistant prostate cancer between May 2014 and November 2015 after receiving several lines of hormonal therapy., Results: A total of 45 patients were given ethinylestradiol before enzalutamide. The prostate-specific antigen response rate (decline in prostate-specific antigen >50% from baseline) of patients receiving ethinylestradiol and enzalutamide were 51.1% and 41.4%, respectively. Cross-resistance between ethinylestradiol and enzalutamide was clearly observed in the setting of pre-docetaxel. In multivariate analysis, the T stage and number of therapies before enzalutamide were the only significant predictors of prostate-specific antigen response to enzalutamide. However, in patients treated pre-docetaxel use, prior use of ethinylestradiol was a significant predictor of prostate-specific antigen response to enzalutamide, whereas ethinylestradiol did not affect the overall survival of these patients., Conclusions: Cross-resistance between ethinylestradiol and enzalutamide in the setting of pre-docetaxel therapy seems to be evident. Therefore, ethinylestradiol should be used prudently before enzalutamide in this setting., (© 2018 The Japanese Urological Association.)
- Published
- 2018
- Full Text
- View/download PDF
21. Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years.
- Author
-
Shida Y, Hakariya T, Miyata Y, and Sakai H
- Abstract
We report three cases of nonmetastatic prostate cancer treated effectively with long-term primary intermittent androgen deprivation (IAD). IAD is not a standard therapy for patients with nonmetastatic prostate cancer. However, based on our experience, we suggest that IAD is one of useful therapeutic tools under certain patients' condition.
- Published
- 2017
- Full Text
- View/download PDF
22. Changes in Lymphangiogenesis and Vascular Endothelial Growth Factor Expression by Neo-Adjuvant Hormonal Therapy in Prostate Cancer Patients.
- Author
-
Asai A, Miyata Y, Matsuo T, Shida Y, Hakariya T, Ohba K, and Sakai H
- Subjects
- Aged, Androgen Antagonists administration & dosage, Cell Line, Tumor, Follow-Up Studies, Humans, Lymphangiogenesis drug effects, Male, Middle Aged, Prostatic Neoplasms genetics, Vascular Endothelial Growth Factor A genetics, Gene Expression Regulation, Neoplastic, Lymphangiogenesis physiology, Neoadjuvant Therapy methods, Prostatic Neoplasms drug therapy, Prostatic Neoplasms metabolism, Vascular Endothelial Growth Factor A biosynthesis
- Abstract
Background: The anti-cancer mechanism of neo-adjuvant hormonal therapy (NHT) is not well understood. Lymphangiogenesis plays an important role in cancer progression and is regulated by a complex mechanism that includes vascular endothelial growth factor (VEGF) signaling. However, there is little information regarding relationship between lymphangiogenesis and androgen deprivation. The aim of this study was to clarify changes in lymphangiogenesis and VEGF expression induced by androgen deprivation in prostate cancer in vivo and in vitro., Methods: Patients who had undergone a radical prostatectomy were enrolled in the study (NHT, n = 60 and non-NHT, n = 64). Lymph vessels were identified by D2-40 immunoreactivity and lymph vessel density and lymph vessel area (LVD and LVA, respectively) were measured from micrographs. The expression of VEGF-A, -B, -C, and -D was evaluated by immunohistochemistry. The prognostic value of LVD and LVA for biochemical recurrence was also investigated., Results: Mean LVD ± SD was higher in the NHT than in the non-NHT group (11.3 ± 3.0 vs. 7.1 ± 3.4 per high power field; P < 0.001). LVA was larger in the NHT than in the non-NHT group (512.8 ± 174.9 vs. 202.7 ± 72.8 µm
2 ; P < 0.001). VEGF-A expression was lower whereas VEGF-C and -D levels were higher in the NHT than in the non-NHT group. VEGF-B expression in specimens with NHT was lower than that in biopsy specimens at diagnosis. These results were confirmed by in vitro studies used androgen-sensitive prostate cancer cell line. LVA was found to be an independent predictor of biochemical recurrence in patients who received NHT., Conclusions: Our results demonstrate that NHT stimulates lymphangiogenesis via upregulation of VEGF-C and -D, which may increase LVA and affect the outcome of prostate cancer patients. This findings were supported by in vitro data of prostate cancer cell. Prostate 77:255-262, 2017. © 2016 The Authors. The Prostate Published by Wiley Periodicals, Inc., (© 2016 The Authors. The Prostate Published by Wiley Periodicals, Inc.)- Published
- 2017
- Full Text
- View/download PDF
23. Comparison Between a Combined Transrectal and Transperineal Approach and a Transrectal Approach for Prostate Rebiopsy.
- Author
-
Shida Y, Hakariya T, Takehara K, Onita T, Miyata Y, and Sakai H
- Subjects
- Adult, Aged, Aged, 80 and over, Humans, Male, Middle Aged, Prostatic Neoplasms pathology, Prostatic Neoplasms surgery, Ultrasound, High-Intensity Focused, Transrectal methods, Biopsy, Large-Core Needle methods, Prostate pathology, Prostatic Neoplasms diagnosis, Transurethral Resection of Prostate methods
- Abstract
Aim: To evaluate whether a combination method involving the transrectal (TR) and transperineal (TP) approach can increase the cancer detection rate relative to the TR approach regarding repeat prostate biopsy., Patients and Methods: One thousand and nineteen patients underwent initial prostate biopsies and 298 repeat prostate biopsies. All initial biopsies were conducted transrectally. Of the repeat biopsies, 179 (60.1%) were performed using the combined transrectal and transperineal (TR+TP) approach; 113 (37.9%) were carried out transrectally. All biopsies were performed under ultrasound guidance using a 16-gauge core biopsy needle; 651 were diagnosed as prostate cancer; 224 patients underwent radical prostatectomies (RPs). We evaluated the cancer detection rates between the biopsy methods in the repeat biopsy cohort and compared the clinical and pathological features of the RP specimens between the initial and repeat biopsy groups., Results: A median of 12 and 20 cores were obtained in the initial and repeat biopsy patients, respectively. Cancer detection rates regarding biopsies 1, 2, 3, 4 and 5 were 49.2% (551/1,119), 34.7% (75/216), 33.3% (20/60), 26.7% (4/15) and 14.3% (1/7), respectively. There were no significant differences between the TR and the TR+TP approach (32.7% vs. 33.5%). RP specimens diagnosed using repeat biopsies showed more anterior dominant tumors relative to those diagnosed using the initial biopsies (59.5% vs. 35.9%; p<0.001)., Conclusion: The TR+TP combination approach could not increase cancer detection rates relative to the TR approach in the repeat biopsy cohort. However, 16-gauge needle biopsy demonstrated acceptable cancer detection rates in the comparatively small number of biopsy cores., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. Human antigen R is positively associated with malignant aggressiveness via upregulation of cell proliferation, migration, and vascular endothelial growth factors and cyclooxygenase-2 in prostate cancer.
- Author
-
Mitsunari K, Miyata Y, Asai A, Matsuo T, Shida Y, Hakariya T, and Sakai H
- Subjects
- Aged, Cell Line, Tumor, Cell Proliferation, Heme Oxygenase-1 metabolism, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Invasiveness, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Predictive Value of Tests, Prostatectomy, Prostatic Neoplasms surgery, Cell Movement, Cyclooxygenase 2 metabolism, ELAV-Like Protein 1 metabolism, Prostatic Neoplasms metabolism, Prostatic Neoplasms pathology, Up-Regulation, Vascular Endothelial Growth Factor A metabolism, Vascular Endothelial Growth Factor C metabolism
- Abstract
Limited information is available on the pathologic significance of human antigen R (HuR) in prostate cancer (PCa). The main aim of this study was to clarify the relationship between HuR expression and malignant aggressiveness, outcome, and expression of cancer-related molecules in PCa. In vitro proliferation, colony formation, and migration assays were performed on LNCaP and PC-3 cells. HuR expression was knocked down (KD) using small interfering RNA. The relationships between HuR expression and the expression of vascular endothelial growth factors (VEGFs), cyclooxygenase (COX)-2, and heme oxygenase (HO)-1 were investigated in PCa cell lines using Western blotting. On KD of HuR, cell proliferation and migration were suppressed in both LNCaP and PC-3 cells, whereas expression of VEGF-A to -D and COX-2 was suppressed in PC-3 but not in LNCaP cells. In addition, expression of these cancer-related factors was analyzed in 182 hormone-naïve PCa and 23 castration-resistant prostate cancer (CRPC) human tissues in vivo. Cytoplasmic (C)-HuR expression was significantly higher in CRPC > hormone-naïve PCa > nontumoral cells. C-HuR expression was positively associated with Gleason score, T stage, and metastasis, and it was considered to be a useful predictor of biochemical recurrence after radical prostatectomy. C-HuR expression was correlated with COX-2 expression in hormone-naïve PCa, and with the expression of VEGF-A, VEGF-C, and COX-2 in CRPC tissues. Our results demonstrated that HuR plays important roles in determining malignant aggressiveness and outcome in PCa, especially in androgen-independent PCa cells, via the regulation of cell proliferation, migration, and expression of VEGF-A, -C, and COX-2., (Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
25. [Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
- Author
-
Hakariya T and Sakai H
- Subjects
- Androgen Antagonists therapeutic use, Androgen Receptor Antagonists therapeutic use, Androgens biosynthesis, Clinical Trials as Topic, Drug Resistance, Neoplasm, Humans, Male, Prostate-Specific Antigen blood, Prostatic Neoplasms, Castration-Resistant diagnosis, Prostatic Neoplasms, Castration-Resistant drug therapy
- Abstract
Enzalutamide and abiraterone acetate are novel drugs for the treatment of castration resistant prostate cancer (CRPC). These agents clearly demonstrated improvements in PFS and OS in patients with CRPC in large randomized Phase III trials. However, the problems exist such as side effects, PSA flare, treatment biomarkers and sequence of the treatment. Further research is necessary to determine the optimal sequence of the treatment or the optimal combination approach with both enzalutamide and abiraterone acetate. It is also necessary to find predictive factors (clinical or molecular) to assist the clinician in making better treatment decisions in an individualized manner.
- Published
- 2016
26. Pheochromocytoma multisystem crisis treated with emergency surgery: a case report and literature review.
- Author
-
Kakoki K, Miyata Y, Shida Y, Hakariya T, Takehara K, Izumida S, Sekino M, Kinoshita N, Igawa T, Fukuoka J, and Sakai H
- Subjects
- Adrenal Gland Neoplasms complications, Adrenal Gland Neoplasms diagnosis, Aged, Humans, Male, Pheochromocytoma complications, Pheochromocytoma diagnosis, Adrenal Gland Neoplasms surgery, Pheochromocytoma surgery
- Abstract
Background: Pheochromocytoma is a neuroendocrine tumor that predominantly presents with hypertension, palpitations, and tachycardia due to excessive catecholamine excretion. Although pheochromocytoma multisystem crisis (PMC) is relatively rare, urologists and clinicians should focus on early diagnosis as delay in initiating the appropriate treatment can lead to mortality, Case Presentation: A 70-year-old man developed ileus after a few days of medication for hypertension. Computed tomography incidentally revealed a left adrenal mass. This finding together with his clinical course was compatible with pheochromocytoma. An α-blocker was administered immediately, and his blood pressure was well controlled. However, his general condition and laboratory data deteriorated rapidly, and the patient was diagnosed with PMC with lethal status. Thus, emergency adrenalectomy was performed without confirmation of catecholamine levels. From the resected specimen, his tumor was judged as pheochromocytoma. On immunohistochemical analysis, the proliferation index evaluated by Ki-67 staining was 9.7 %. This case report was approved by the Human Ethics Review Committee of the Nagasaki University Hospital., Conclusion: The present case of PMC was successfully treated with emergency surgery. The benign pheochromocytoma also presented with high cell proliferation potential, which may be a cause of the extreme aggressiveness of PMC.
- Published
- 2015
- Full Text
- View/download PDF
27. Composite pheochromocytoma of the adrenal gland: a case series.
- Author
-
Shida Y, Igawa T, Abe K, Hakariya T, Takehara K, Onita T, and Sakai H
- Subjects
- Adrenal Gland Neoplasms metabolism, Adrenal Gland Neoplasms pathology, Adrenal Glands metabolism, Adrenal Glands pathology, Adrenalectomy, Adult, Female, Ganglioneuroblastoma metabolism, Ganglioneuroblastoma pathology, Ganglioneuroma metabolism, Ganglioneuroma pathology, Gene Expression, Humans, Laparoscopy, Male, Middle Aged, Pheochromocytoma metabolism, Pheochromocytoma pathology, Treatment Outcome, Adrenal Gland Neoplasms surgery, Adrenal Glands surgery, Biomarkers, Tumor genetics, Ganglioneuroblastoma surgery, Ganglioneuroma surgery, Ki-67 Antigen genetics, Pheochromocytoma surgery
- Abstract
Background: Composite pheochromocytoma is a rare pathological condition characterized by elements of both pheochromocytoma and neurogenic tumors. However, detailed clinical outcomes of this tumor have not been fully shown. From 2007 to 2013, we experienced three cases of adrenal composite pheochromocytoma. In this report, we investigate the clinicopathological features of these three cases of composite pheochromocytoma and compare them with previously reported cases., Case Presentations: Cases 1 and 2 were a 29-year-old Japanese woman and a 59-year-old Japanese man, respectively. They underwent laparoscopic left adrenalectomy, and pathological examination revealed composite pheochromocytoma-ganglioneuroma. Case 3 was a 53-year-old Japanese man who had been receiving hemodialysis for 17 years. He underwent laparoscopic right adrenalectomy, and pathological examination revealed composite pheochromocytoma-ganglioneuroblastoma. Although the Ki67-positive rates varied from 1.0 to 6.2% among the three cases, no clinical recurrences occurred. Despite the relatively high rate of Ki67 positivity, complete tumor resection resulted in favorable clinical outcomes., Conclusion: We experienced three cases of adrenal composite pheochromocytoma. Although the clinical findings and treatment outcomes of composite pheochromocytoma were similar to those of ordinary pheochromocytoma, further studies of the biological behavior and genetic profiles of composite pheochromocytoma are necessary to achieve a better understanding of this tumor.
- Published
- 2015
- Full Text
- View/download PDF
28. [A case of extramammary Paget's disease with urethral invasion treated by construction of continent urinary diversion based on the Monti principle using the sigmoid colon].
- Author
-
Hakariya T, Nakanishi H, Asai A, Kanokoki K, Kihara T, Takehara K, Igawa T, Sakai H, Tou K, Takeshita H, Miura K, Tanaka K, Kashima S, and Matsuo M
- Subjects
- Aged, Female, Humans, Neoplasm Invasiveness, Paget Disease, Extramammary pathology, Urethra surgery, Vulvar Neoplasms pathology, Colon, Sigmoid surgery, Paget Disease, Extramammary surgery, Urethra pathology, Urinary Diversion methods, Vulvar Neoplasms surgery
- Abstract
Extramammary Paget's disease occurring in the female vulva is occasionally associated with invasive disease to urethra and bladder mucosa. For such cases, ensuring adequate surgical margin is essential. Not only adequate removal of tumor, but also urinary diversion is important for patient's quality of life. A 77- year-old woman was treated with excision of vulvar tumor, urethra, vagina, rectum and anus. The determination of excision area was decided according to the result of mapping biopsy including urethra and bladder. Then she received reconstruction of vulva using the gracilis muscle skin flap. We applied a technique of channel formation for intermittent catheterization using the retubularized sigmoid colon based on the Monti principle. The tube was implanted submucosally into the bladder to prevent the reflux of urine. Fifteen days after operation, self-intermittent catheterization was started successfully. Surgical margins were negative in urethra, skin, vagina and rectum. There are no obvious recurrence or metastasis 1 year after surgery.
- Published
- 2015
29. Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer.
- Author
-
Hakariya T, Obata S, Igawa T, and Sakai H
- Subjects
- Aged, Aged, 80 and over, Feasibility Studies, Humans, Male, Middle Aged, Prostate-Specific Antigen blood, Prostatic Neoplasms, Castration-Resistant blood, Prostatic Neoplasms, Castration-Resistant mortality, Radiotherapy Dosage, Radiotherapy, Intensity-Modulated adverse effects, Prostatic Neoplasms, Castration-Resistant radiotherapy, Radiotherapy, Intensity-Modulated methods
- Abstract
Aim: We examined the feasibility of local intensity-modulated radiation therapy (IMRT) with pelvic irradiation using the simultaneous integrated boost (SIB) technique to treat patients with castration-resistant prostate cancer (CRPC) after several lines of hormonal therapy., Patients and Methods: Data from 10 consecutive patients with CRPC treated with SIB-IMRT between November 2001 and September 2009 were analyzed retrospectively., Results: A decline in prostate-specific antigen (PSA) level was observed in all cases after SIB-IMRT. Biochemical progression-free survival at 5 years was 70% with a median follow-up of 33.5 months after SIB-IMRT. All patients completed SIB-IMRT without delay due to acute toxicity. The PSA nadir after first-line hormonal therapy, the PSA before SIB-IMRT, the PSA doubling time before SIB-IMRT and the PSA nadir after SIB-IMRT were significant factors for biochemical progression after SIB-IMRT., Conclusion: SIB-IMRT for patients with CRPC is feasible and has a satisfactory effect in terms of disease control., (Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2014
30. [III. Prostate cancer].
- Author
-
Takehara K, Hakariya T, and Sakai H
- Subjects
- Androgen Antagonists therapeutic use, Androgens metabolism, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Humans, Male, Prostatic Neoplasms drug therapy
- Published
- 2014
31. [Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication].
- Author
-
Sakai H, Igawa T, Onita T, Furukawa M, Hakariya T, Hayashi M, Matsuya F, Shida Y, Nishimura N, Yogi Y, Tsurusaki T, Takehara K, Nomata K, Shiraishi K, Shono T, Aoki D, and Kanetake H
- Subjects
- Adrenergic alpha-Antagonists adverse effects, Aged, Aged, 80 and over, Drug Administration Schedule, Humans, Male, Middle Aged, Naphthalenes adverse effects, Piperazines adverse effects, Prostatic Hyperplasia complications, Urinary Bladder, Overactive etiology, Adrenergic alpha-Antagonists administration & dosage, Naphthalenes administration & dosage, Piperazines administration & dosage, Prostatic Hyperplasia drug therapy, Urinary Bladder, Overactive drug therapy
- Abstract
A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration.
- Published
- 2011
32. Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
- Author
-
Ide S, Soda H, Hakariya T, Takemoto S, Ishimoto H, Tomari S, Sawai T, Nagashima S, Furukawa M, Nakamura Y, and Kohno S
- Subjects
- Asian People, Bone Neoplasms drug therapy, Bone Neoplasms secondary, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell secondary, Humans, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology, Lung Diseases, Interstitial physiopathology, Lung Neoplasms pathology, Lung Neoplasms therapy, Male, Middle Aged, Niacinamide analogs & derivatives, Phenylurea Compounds, Sorafenib, Antineoplastic Agents adverse effects, Benzenesulfonates adverse effects, Lung Diseases, Interstitial chemically induced, Pyridines adverse effects
- Abstract
There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences., (Copyright 2009 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
33. p38MAPK activation is involved in androgen-independent proliferation of human prostate cancer cells by regulating IL-6 secretion.
- Author
-
Shida Y, Igawa T, Hakariya T, Sakai H, and Kanetake H
- Subjects
- Androgens physiology, Anthracenes pharmacology, Cell Line, Tumor, Enzyme Activation, Extracellular Signal-Regulated MAP Kinases biosynthesis, Flavonoids pharmacology, Humans, Imidazoles pharmacology, Male, Prostatic Neoplasms metabolism, Pyridines pharmacology, Ritodrine, p38 Mitogen-Activated Protein Kinases antagonists & inhibitors, Cell Proliferation drug effects, Interleukin-6 metabolism, Prostatic Neoplasms pathology, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Increased levels of serum interleukin-6 (IL-6) are frequently observed in patients with advanced, hormone-refractory prostate cancer. However, the precise mechanism of IL-6 regulation is still largely unknown. Since prostate cancer gradually progresses to an androgen-independent state despite the stress caused by various therapeutic agents, we hypothesized the stress-activated protein kinases (SAPKs) involvement in androgen-independent growth or IL-6 secretion of prostate cancer cells. Using PC-3 and DU145 human prostate cancer cells, we analyzed the role of SAPKs in IL-6 mediated cell growth and found that the p38MAPK and JNK are involved in androgen-independent cancer cell growth. Furthermore, IL-6 secretion by PC-3 and DU145 cells was significantly suppressed by SAPKs inhibitor, especially by p38MAPK inhibitor SB203580, but not by JNK inhibitor SP600125 nor by MEK inhibitor, PD98059. These results raised the possibility that the IL-6 mediated androgen-independent proliferation of PC-3 and DU145 cells is regulated at least partly via SAPKs signaling pathway especially through p38MAPK activation.
- Published
- 2007
- Full Text
- View/download PDF
34. EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells.
- Author
-
Hakariya T, Shida Y, Sakai H, Kanetake H, and Igawa T
- Subjects
- Androgens metabolism, Androgens pharmacology, Cell Line, Tumor, Chromones pharmacology, Down-Regulation, Epidermal Growth Factor metabolism, Epidermal Growth Factor pharmacology, ErbB Receptors antagonists & inhibitors, Gene Expression Regulation, Neoplastic drug effects, Humans, Immunohistochemistry, Male, Morpholines pharmacology, Neoplasm Staging, Organic Chemicals pharmacology, Prostatic Neoplasms pathology, Protein Kinase Inhibitors pharmacology, ErbB Receptors metabolism, Phosphatidylinositol 3-Kinases metabolism, Prostate-Specific Antigen metabolism, Prostatic Neoplasms metabolism, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects
- Abstract
Epidermal growth factor (EGF) and its receptor (EGFR) are involved in hormone-refractory growth and poor prognosis of a subgroup of human prostate cancer. In this communication, we investigated the regulation of PSA by the EGFR signaling pathway using LNCaP C-81 prostate cancer cells. Administration of EGF stimulated the growth of LNCaP C-81 cells, however, PSA expression and secretion were suppressed. An EGFR inhibitor, AG1478, abrogated the PSA suppression effect by EGF, in concurrence with the suppression of tyro-phosphorylation levels of EGFR. Interestingly, the AR level was also decreased in EGF-treated LNCaP C-81 cells. Moreover, LY294002, but not PD98059, inhibited the PSA and AR suppression effect by EGF in concurrence with the suppression of phosphorylation levels of Akt. In conclusion, our results strongly suggest the existence of a novel androgen-independent PSA regulatory mechanism, i.e., the EGFR signaling pathway negatively regulates PSA expression which may be induced by the alteration of AR expression via the PI3K-Akt pathway in LNCaP C-81 cells.
- Published
- 2006
- Full Text
- View/download PDF
35. [Efficacy of periprostatic nerve blockade during ultrasound-guided transrectal 10-core biopsy of the prostate].
- Author
-
Hakariya T, Hatada T, Miyata Y, Igawa T, Sakai H, and Kanetake H
- Subjects
- Humans, Male, Pain Measurement, Prostate diagnostic imaging, Ultrasonography, Anesthesia, Local, Biopsy, Needle methods, Nerve Block, Prostate pathology
- Abstract
Purpose: We examined the efficacy and safety of periprostatic nerve blockade during transrectal ultrasound guided prostate biopsy., Materials and Methods: Transrectal ultrasound guided 10 core biopsy of the prostate was performed in 116 consecutive men. From March 2002 to July 2003, 58 men underwent biopsy of the prostate without local anesthesia (control group). From August 2003 to March 2004, 58 men received periprostatic nerve blockade before prostate biopsies (anesthesia group). A 4-ml dose of 1% lidocaine was injected at 2 or 3 locations on each side of the prostate via a 23 gauge needle. Pain during biopsy was questioned using a 5-point Face scale and complications were also recorded., Results: The average pain score during biopsy was 1.9 in the anesthesia group versus 3.1 in the control group (p<0.001). In the anesthesia group 20.7% of patients had a pain score 3 or greater than 3 versus 69% in the control group. The complication rate showed no significant difference between the two groups., Conclusions: Periprostatic nerve blockade is a safe and effective method of anesthesia for transrectal prostate biopsy.
- Published
- 2005
- Full Text
- View/download PDF
36. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment.
- Author
-
Miyata Y, Kanda S, Sakai H, Hakariya T, and Kanetake H
- Subjects
- Adenocarcinoma metabolism, Aged, Humans, Immunohistochemistry, In Situ Nick-End Labeling, Male, Prostatectomy, Prostatic Neoplasms metabolism, Prostatic Neoplasms therapy, Adenocarcinoma pathology, Antineoplastic Agents, Hormonal therapeutic use, Apoptosis, Cell Proliferation, Neoadjuvant Therapy, Prostatic Neoplasms pathology, Proto-Oncogene Proteins c-bcl-2 metabolism, bcl-2-Associated X Protein metabolism
- Abstract
Objectives: To investigate the relationships between changes in the carcinoma cell proliferation index, apoptotic index (AI), and apoptosis-related factors, including bcl-2 and bax, after different durations of neoadjuvant hormonal therapy (NHT) in prostate cancer tissue., Methods: Pre- and post-NHT specimens were obtained from 42 patients who had undergone NHT and radical prostatectomy. The patients were divided into two groups according to the duration of NHT: group 1 (3 to 7 months, n = 21) and group 2 (8 to 12 months, n = 21; no randomization). Immunohistochemistry was used to determine the expression of bcl-2 and bax and to determine the proliferation index, and the terminal deoxynucleotidyl transferase-mediated nick end-labeling method was used to assess apoptosis and determine the AI., Results: The median proliferation indexes of groups 1 (1.8%) and 2 (1.6%) were significantly lower than the respective values in the pre-NHT specimens (4.9%, P < 0.01). The median AI of group 1 (2.5%) was greater than in the pre-NHT specimens (1.4%). In addition, the post/pre-NHT AI ratio correlated significantly with the duration of NHT in group 1 (r = 0.58, P < 0.01), but not in group 2. Bax expression increased in a manner parallel to that of the AI., Conclusions: NHT suppresses prostate cancer cell proliferation for 3 to 12 months. Although the AI was increased during 3 to 7 months of NHT, no significant difference was found between the pre-NHT levels and those after 8 to 12 months. Our results support the current belief that the optimal duration of NHT is longer than 3 months.
- Published
- 2005
- Full Text
- View/download PDF
37. [Feasibility and change in the level of blood paclitaxel concentration after paclitaxel therapy for a hemodialysis patient with cisplatin resistant metastatic transitional cell cancer].
- Author
-
Nomata K, Sagara Y, Toubu S, Hakariya T, Tsuda S, Noguchi M, Eguchi J, and Kanetaka H
- Subjects
- Carcinoma, Transitional Cell secondary, Cisplatin pharmacology, Cystectomy, Drug Administration Schedule, Drug Resistance, Neoplasm, Feasibility Studies, Female, Humans, Kidney Failure, Chronic therapy, Kidney Neoplasms drug therapy, Kidney Neoplasms secondary, Lung Neoplasms secondary, Middle Aged, Urinary Bladder Neoplasms surgery, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic blood, Carcinoma, Transitional Cell drug therapy, Paclitaxel administration & dosage, Paclitaxel blood, Renal Dialysis, Urinary Bladder Neoplasms drug therapy
- Abstract
The patient was a 54-year-old woman with recurrent urinary tract cancer. A CT of the lung showed multiple nodules after bil-nephroureterectomy, cystectomy and combination chemotherapy with cisplatin (CDDP) and epirubicin (EPI). As second line chemotherapy for the patient, TXL was administered. She was hemodialized after operation, and there are few reports about paclitaxel (TXL) therapy for hemodialysis (HD) patients. Peak blood TXL concentration, about 1,200 ng/ml, was achieved 6 hours after the administration of TXL. The blood TXL concentration was 41 ng/ml 24 h after the administration of TXL. However, the TXL therapy was not repeated because of unacceptable neurological side effects. An almost 40% shrinkage in the size of the metastatic lung nodule was obtained after 1 cycle of treatment.
- Published
- 2002
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.